We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Hybrigenics Participates in the MASTERSWITCH European Project
News

Hybrigenics Participates in the MASTERSWITCH European Project

Hybrigenics Participates in the MASTERSWITCH European Project
News

Hybrigenics Participates in the MASTERSWITCH European Project

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Hybrigenics Participates in the MASTERSWITCH European Project"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced that it has signed a substantial contract as part of a large-scale European Union research project called MASTERSWITCH.

Hybrigenics will deploy its protein interaction expertise in the field of chronic inflammatory diseases. The company will develop a high throughput assay and screen its diverse 100,000 compound library and its collection of about 2,000 natural substances. The aim is to identify small-molecule inhibitors of a therapeutically relevant protein interaction.

A hit-to-lead optimization program will then be conducted in close collaboration with Dr. Frederique Ponchel (Leeds Institute of Molecular Medicine, UK) and Prof. Richard Aspinall (Translational Medicine, Cranfield University, UK).

Hybrigenics will receive more than EUR 400,000 over the first two years of the five year-long consortium agreement. "This EU contract is the recognition at international level of the excellence of Hybrigenics' expertise in this area of protein interaction assay development and screening," said Remi Delansorne, CEO at Hybrigenics.
Advertisement